The Claim
Among adults prescribed GLP-1 receptor agonists for weight management, 79% of liraglutide users and 53% of semaglutide users discontinue treatment within one year.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Among adults taking GLP-1 receptor agonists to lose weight, 79% of those taking liraglutide and 53% of those taking semaglutide stop treatment within one year.
See the scientific wording
In adults prescribed GLP-1 receptor agonists for weight management, discontinuation rates are high, with 79% of liraglutide users and 53% of semaglutide users stopping treatment within one year, suggesting adherence challenges may influence observed outcomes.
The drug irritates the stomach and intestines, causing nausea, vomiting, and feeling full quickly. These effects become so uncomfortable that people stop taking the medicine.
What the research says
1 studyThe study didn’t directly count how many people stopped taking the drugs, but it found that semaglutide worked better after six months, which suggests more people kept taking it compared to liraglutide — supporting the idea that more people quit liraglutide.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.